ACRS - アクラリス・セラピュ―ティクス （Aclaris Therapeutics Inc.）

WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today is providing a corporate outlook for 2023.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Aclaris, Astellas, Biocon, CMS Aesthetics, Cosmo, ERS Genomics, Focus-X, Full-Life Technologies, Immutep, Incyte, Legochem, Merck KGaA, Pediatrix, Pfizer, Sirona, Sotio, Viatris, Wanbang.

According to Benzinga Pro data, during Q3, Aclaris Therapeutics (NASDAQ: ACRS ) posted sales of $19.02 million. Earnings were up 2.82%, but Aclaris Therapeutics still reported an overall loss of $19.95 million. Aclaris Therapeutics collected $1.53 million in revenue during Q2, but reported earnings showed a $20.53 million loss. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth … Full story available on Benzinga.com

Aclaris Therapeutics (ACRX), a biopharma focused on immune-inflammatory diseases, ticked higher on Thursday after Goldman Sachs launched its coverage with a Buy recommendation and a $25…

WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-focused therapeutic company, today announced that the companies have entered into a license agreement. Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and commercialize ATI-1777, Aclaris’ investigational “soft” Janus kinase (JAK) 1/3 inhibitor, for any disease, including atopic dermatitis, in Greater China (Mainland China, Hong Kong, Macau and Taiwan). Aclaris will retain the rights to develop, manufacture and commercialize ATI-1777 in the rest of the world.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Aclaris, Astellas, Biocon, CMS Aesthetics, Cosmo, ERS Genomics, Focus-X, Full-Life Technologies, Immutep, Incyte, Legochem, Merck KGaA, Pediatrix, Pfizer, Sirona, Sotio, Viatris, Wanbang.

According to Benzinga Pro data, during Q3, Aclaris Therapeutics (NASDAQ: ACRS ) posted sales of $19.02 million. Earnings were up 2.82%, but Aclaris Therapeutics still reported an overall loss of $19.95 million. Aclaris Therapeutics collected $1.53 million in revenue during Q2, but reported earnings showed a $20.53 million loss. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth … Full story available on Benzinga.com

Aclaris Therapeutics (ACRX), a biopharma focused on immune-inflammatory diseases, ticked higher on Thursday after Goldman Sachs launched its coverage with a Buy recommendation and a $25…

WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-focused therapeutic company, today announced that the companies have entered into a license agreement. Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and commercialize ATI-1777, Aclaris’ investigational “soft” Janus kinase (JAK) 1/3 inhibitor, for any disease, including atopic dermatitis, in Greater China (Mainland China, Hong Kong, Macau and Taiwan). Aclaris will retain the rights to develop, manufacture and commercialize ATI-1777 in the rest of the world.

Aclaris Therapeutics (ACRS) said Tuesday co-founder and current CEO Neal Walker will transition to the role of board chair, effective Jan

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Aclaris, Astellas, Biocon, CMS Aesthetics, Cosmo, ERS Genomics, Focus-X, Full-Life Technologies, Immutep, Incyte, Legochem, Merck KGaA, Pediatrix, Pfizer, Sirona, Sotio, Viatris, Wanbang.

According to Benzinga Pro data, during Q3, Aclaris Therapeutics (NASDAQ: ACRS ) posted sales of $19.02 million. Earnings were up 2.82%, but Aclaris Therapeutics still reported an overall loss of $19.95 million. Aclaris Therapeutics collected $1.53 million in revenue during Q2, but reported earnings showed a $20.53 million loss. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth … Full story available on Benzinga.com

Aclaris Therapeutics (ACRX), a biopharma focused on immune-inflammatory diseases, ticked higher on Thursday after Goldman Sachs launched its coverage with a Buy recommendation and a $25…

WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-focused therapeutic company, today announced that the companies have entered into a license agreement. Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and commercialize ATI-1777, Aclaris’ investigational “soft” Janus kinase (JAK) 1/3 inhibitor, for any disease, including atopic dermatitis, in Greater China (Mainland China, Hong Kong, Macau and Taiwan). Aclaris will retain the rights to develop, manufacture and commercialize ATI-1777 in the rest of the world.

Aclaris Therapeutics (ACRS) said Tuesday co-founder and current CEO Neal Walker will transition to the role of board chair, effective Jan